Key result
Statin use in patients with chronic obstructive pulmonary disease was associated with a 38% reduction in all-cause mortality compared to statin non-users.
Why the study?
Does statin use reduce mortality and exacerbations in patients with COPD?
Meta-Analysis (n=238,459)
Does statin use reduce mortality and exacerbations in patients with COPD?
In patients with COPD, statin use is associated with significant reductions in all-cause mortality, COPD mortality, and COPD exacerbations.
Answers are grounded in this paper and cite their sources.
May support statin consideration in COPD for mortality reduction; leaves open causality pending RCTs.
The objective of this study is to assess whether statin use is associated with beneficial effects on COPD outcomes. We conducted a systematic review and meta-analysis of all available studies describing the association between statin use and COPD mortality, exacerbations and cardiovascular events. Medline, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials were searched, with no restrictions. The hazard ratio (HR) with 95% confidence interval (CI) was estimated. Fifteen studies with a total of 238,459 patients were included. Nine articles provided data on all-cause mortality (124,543 participants), and they gave a HR of 0.62 (95% CI 0.52 to 0.73). Three studies provided data on cancer mortality (90,077 participants), HR 0.83 (0.65 to 1.08); four studies on COPD mortality (88,767 participants), HR 0.48 (0.23 to 0.99); and three studies on cardiovascular mortality (90,041 participants), HR 0.93 (0.50 to 1.72). Six articles provided data on COPD exacerbation with or without hospitalization (129,796 participants), HR 0.64 (0.55 to 0.75). Additionally, the use of statins was associated with a significant reduction risk of myocardial infarction, but not for stroke. Our systematic review showed a clear benefit of statins in patients with COPD.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2015) conducted a meta-analysis in Chronic obstructive pulmonary disease (COPD) (n=238,459). Statins vs. Statin non-users was evaluated on All-cause mortality (HR 0.62, 95% CI 0.52 to 0.73). Statin use in patients with chronic obstructive pulmonary disease was associated with a 38% reduction in all-cause mortality compared to statin non-users.
Synapse has enriched 10 related papers. Consider them for comparative context: